Article Details

Durvalumab by AstraZeneca for Esophageal Cancer: Likelihood of Approval

Retrieved on: 2023-10-27 22:10:03

Tags for this article:

Click the tags to see associated articles and topics

Durvalumab by AstraZeneca for Esophageal Cancer: Likelihood of Approval. View article details on HISWAI: https://www.pharmaceutical-technology.com/uncategorized/durvalumab-astrazeneca-esophageal-cancer-likelihood-of-approval-2/

Excerpt

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs ...

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up